Y-mAbs Therapeutics, Inc. (YMAB)
- Previous Close
11.82 - Open
12.03 - Bid 12.16 x 200
- Ask 12.25 x 200
- Day's Range
12.03 - 12.75 - 52 Week Range
4.60 - 20.90 - Volume
263,697 - Avg. Volume
377,616 - Market Cap (intraday)
551.222M - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
-- - EPS (TTM)
-0.49 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.14
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
www.ymabs.comRecent News: YMAB
Performance Overview: YMAB
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: YMAB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: YMAB
Valuation Measures
Market Cap
518.69M
Enterprise Value
444.12M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.11
Price/Book (mrq)
5.23
Enterprise Value/Revenue
5.26
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-25.64%
Return on Assets (ttm)
-12.02%
Return on Equity (ttm)
-20.93%
Revenue (ttm)
84.5M
Net Income Avi to Common (ttm)
-21.67M
Diluted EPS (ttm)
-0.49
Balance Sheet and Cash Flow
Total Cash (mrq)
75.75M
Total Debt/Equity (mrq)
1.19%
Levered Free Cash Flow (ttm)
-11.46M
Research Analysis: YMAB
Company Insights: YMAB
YMAB does not have Company Insights